dose. Moreover, some patients develop secondary effects such as myalgia or myopathy, but others do not. These 2 aspects suggest that there could be a genetic influence on the efficacy of statin treatment. Thus, we aimed to investigate it through the study of some gene variants, all of them related to lipid metabolism or to pharmacokinetics-pharmacodynamics of statins. The 5 genes and 6 variants were as follows: APOE (rs7412 and rs429358), HMGCR (rs3846662), SLCO1B1 (rs4149056), CYP3A4 (rs2740574), and LPA (rs10455872).
APOE variants (APOE2 c.526C > T, rs7412, and APOE4 c.388T > C, rs429358) have already been related to lipid concentration and cardiovascular risk [9] [10] [11] [12] ; besides, apoE has a paramount implication in lipoprotein metabolism. The chosen HMGCR variant (c.1564-106A > G) is related to a functional polymorphism that produces an RNA without exon 13, resulting in an enzyme with an inactive catalytic site, and a likely loss of sensibility for statin binding. 13, 14 SLCO1B1 codes for a transport protein essential for the entry of statins to the hepatocytes. The variant c.521T > C produces a loss of activity of the protein and it is known to be related to the development of secondary effects of statin treatment. [15] [16] [17] codes for an isoform of P450 cytochrome, and it is involved in the initial metabolism of statins, reducing their bioavailability. The variant (c.-392G > A) inhibits the binding of a repressor to the promoter, so there is an over-expression of the protein and a greater degradation of the drug. 18 LPA codes for lipoprotein (a), presently considered as an emerging risk factor because it is an atherogenic protein related to low-density lipoprotein. Some authors described an association between the variant (LPA c.3947 + 467T > C) and the response to statins.
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| MATERIAL S AND ME THODS
| Study population
All patients were attended in the vascular risk unit (VRU) of the Bellvitge Universitary Hospital between 1994 and 2012. Exclusion criteria for this study were as follows: initial serum TC concentration (TCi) lower than 5.2 mmol/L or higher than 13 mmol/L, second visit after more than 1-year, concomitant treatment with interfering drugs and other hypolipemiant drugs. Final population consisted of 100 patients; none had been treated before starting the study.
Patients received different statins at different doses, and conversion tables were employed to standardize all statin doses to simvastatin (https://www.fda.gov/Drugs/DrugSafety/ucm256581. htm).
| Genotyping and biochemical analysis
DNA was extracted from peripheral blood with the High Pure™ PCR Template Preparation Kit (Roche, Germany).
For CYP3A4 analysis, DNA was amplified by PCR employing the primers 5′-GGACAGCCATAGAGACAACTGCA-3′ and 5′-CTTTCCTGCCCTGCACAG-3′ followed by RFLP (restriction fragment length polymorphism), with Pst I restriction enzyme.
SLCO1B1, HMGCR, and LPA variants were analyzed by real-time PCR using TaqMan allelic discrimination assays (Life Technologies, CA, USA). In the case of APOE variants, some samples were analyzed by PCR-RFLP, 23 and then the technology was replaced by real-time PCR with TaqMan assays, after checking the interchangeability of methods.
Serum total cholesterol (TC) and cholesterol from HDL (HDL)
were measured in a Cobas 711 analyzer (Roche Diagnostics), and serum cholesterol excluded from HDL (non-HDL) was calculated (non-HDL = TC − HDL).
| Treatment efficacy indicators
Two aspects were studied as follows: first, the percent change of TC and non-HDL cholesterol between the first and the second visit 
| Control variables
Every patient was surveyed in each visit to the hospital and the data recorded were as follows: body mass index (BMI), smoking pattern (present smoker, nonsmoker, and former smoker), physical exercise (hours/wk), alcohol intake (g/d), diabetes (yes/no) (DM), hypertension (yes/no) (HT), and previous ischemic event (yes/no) (I). Date and treatment changes were also registered. With this information, the control variables constructed were as follows: percent change in BMI (∆BMI), total change in alcohol intake (∆A), exercise practice (∆E) and smoking habits (∆S), and mean daily statin dose (D). Sex, age, DM, I and HT were also considered as control variables.
These variables have been related to circulating lipid concentrations and cardiovascular risk. The influence of the genetic variants on statin efficacy was evaluated independently and together with these variables.
Before introducing nongenetic variables in the model, a correlation study was carried out to evaluate the relationship between them. In case of high correlation between 2 variables, only one of them (the best related to lipid change) was included in the model.
| Statistics
The influence of the genetic variants on statin efficacy was assessed by constructing several regression models in several steps: well-defined groups: One of them included variants with an associated near-significance P around .1, while the rest had a much higher P value.
| RE SULTS
The correlation study only showed a moderate correlation between the variables DM and I (ρ = .570 and P = .001). The variable I also presented low correlation with another 2 variables: D (ρ = .294 and P = .007) and ΔS (ρ = .268 and P = .034). In consequence, I was not included in the models. Table 1 shows the initial data of the patients. Mean TC concentration was, by inclusion criteria, higher than 5.2 mmol/L, and mean non-HDL was higher than the discriminant value (4.2 mmol/L), as expected for patients who require lipid-lowering treatment. Most patients (67%) were men, as it could be expected according to the relationship between dyslipidemia and gender. About one-third of the patients were active smokers, and only few patients were diabetic or hypertensive or had suffered an ischemic event before the study.
In a minority of cases (between 6% and 19%), there were no data available for these variables.
To build up regression models based on nongenetic control variables with a significant influence on the percent reduction in TC and non-HDL cholesterol, individual regressions were calculated for each variable. (Table 4) .
On the other hand, a X 2 test was developed to compare the indicators between carriers and noncarriers of the gene variants. The results are shown in Table 3 . Only 1 gene variant was selected to study its possible influence on statin efficacy, the HMGCR c.1564-106A > G variant (bold in Table 3 ), because it had a clearly lower and almost significant P value. The variant showed a harmful effect:
Carriers showed lower reductions of TC and non-HDL with statin therapy.
Therefore, the expanded model was constructed with the selected control variables and the HMGCR c.1564-106A > G variant. Concerning to therapeutic goals achievement, as shown in Table 5 , only 1 control variable could be selected for each basal model: the initial concentration of total cholesterol (TCi; P = .005) and of non-HDL cholesterol (non-HDLi), respectively, in the last case because it was also the only control variable whose significant level was lower than .1 (P = .094). However, no basal model was Some other studies have already evaluated non-HDL cholesterol concentrations in patients treated with statins, demonstrating the high relationship between its concentration and cardiovascular diseases. 27 Also, as the National Lipid Association guideline proposed non-HDL goals both for patients at very high cardiovascular risk and high cardiovascular risk, some recent studies employ the percent reduction in non-HDL to evaluate treatment efficacy. 28 This US association considers non-HDL concentration as a primary therapy goal, although European guides still consider it as a secondary target. 28, 29 In our study, none of the patients had been treated with lipid- .007
B (IC 95%), coefficient B with confidence interval 95%; D, statin daily dose; ΔE, changes in physical exercise practice; non-HDL, non-HDL cholesterol; P, associated probability; R 2 , coefficient of determination; TC, total cholesterol.
allele was associated with lower reductions of non-HDL cholesterol, but in others, this effect was not observed, [31] [32] [33] as is the case in our study. CYP3A4 variant causes a reduction in statins bioavailability, and some authors have related it to lower reductions of LDL cholesterol after statin treatment, 34 although we could not find it relevant. LPA codes for lipoprotein (a), which is presently considered as a nonconventional risk factor. Some authors described an asso- There is no consensus about the influence of rs3846662 on sta- OR, odds ratio with confidence interval 95%; P, associated probability; TCi, initial total cholesterol concentration.
women 37 or in general population. 38 Some of these works have proposed a way to explain the influence. HMGCR gene codes for the key enzyme of the endogenous synthesis of cholesterol, and rs3846662
variant is related to the production of an alternatively spliced RNA without exon 13. 38 The corresponding defective protein has an altered catalytic site making the binding to statins more difficult 38 and hindering these drugs effect on lipid lowering. Exon 13 skipping impairs enzymatic activity. 39 Some studies have demonstrated that all cells have both the complete protein (HMGCR+) and the defective 1 (HMGCR−) in different proportions, and people/cells without rs3846662 variant present a higher (HMGCR−) proportion.
14,40
Besides, there is an extra regulation of these proportions in noncarriers (AA genotype): When circulating lipids decrease, the fraction of (HMGCR+) increases and that of (HMGCR−) decreases. This regulation has not been observed in carriers (AG and GG genotypes). 40 The other variant which showed some influence on achieving goals was APOE2 c.526C > T, but in the expanded model, it did not reach the defined significance level. Given that the minor allele, T, has a very low frequency, it is possible that with a higher popula- In conclusion, our results show a modest relation between the presence of the HMGCR rs3846662 variant and a worse response to statins, and are consistent with recently published proposals of molecular ways to explain it. However, it would be advisable to confirm our results in a larger population.
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